Julie Lellouche, Author at Labiotech.eu

About

Blogger for Labiotech.eu. Entrepreneurial Student at SupBiotech, Paris Higher Biotechnology Institute.

Articles by Julie Lellouche

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

Deinocossus Synthetic biology france leading

News and Trends 18 Nov 2014

Is France Leading the European Synthetic Biology-Based Biofuel Field?

France has great Synthetic Biology Biotech companies. Paris-based Global Bioenergies carried out the first isobutene production trial in its industrial pilot of Pomacle-Bazancourt in the east of France. Two other companies, Deinove and Fermentalg are growing extremely fast, and giant Total is investing massively in the field. Is France on the good way to become […]

November 18, 2014 - 3 minutesmins - By Julie Lellouche

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year. It is a huge step forward in treating type 2 diabetes. Indeed, most people forget […]

November 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Nov 2014

A Way to Control Genes within Human Brain?

Researchers at the Department of Biosystems in Basel have developed a novel gene regulation method that enables thought-specific brainwaves to control the conversion of genes into proteins, so the genes expression. It opens new ways to control gene expression within your brain and could lead to brain surgeries. In this new study, bioengineers placed implants inside […]

November 14, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Nov 2014

Ziarco Pharma raises €27M two years after founding

Ziarco Group Ltd, a British biopharmaceutical start-up focusing on inflammatory skin diseases, bags €27M for Series B financing round. This fast-growing 2 year old company already raised €21.4M in a Serie A lead by Pfizer and is now accelerating even more. This second fundraising will enable clinical Phase II Proof-of-Concept studies for ZPL-389, a histamine H4 receptor antagonist […]

November 11, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 6 Nov 2014

The First Patient Receives an Implant Pump System to manage Pleural Effusions

For the first time, a pleurapump system designed to manage chronic pleural effusions was implanted in a patient in Marseille (France). This is an innovative device from Sequana Medical AG, a private Swiss medical device company. Chronic pleural effusions is recurrence of excess fluid which collects around the lungs. The most common causes of it are congestive heart […]

November 6, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 4 Nov 2014

Novo Nordisk invests €104M in new laboratory for Diabetes

Danish insulin giant Novo Nordisk has made a 104 million euros investment in new laboratories at the company’s research and development campus. Based in Malov in Denmark, the lab is expected to be ready for occupation in early 2016. The new facility, Diabetes Research House, will accommodate approximately 350 employees. During the construction phase, the project […]

November 4, 2014 - 1 minutemin - By Julie Lellouche

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 28 Oct 2014

Stem Cell Therapy for Degenerative Muscle Disease thanks to ENDOSTEM Project

ENDOSTEM project aims to identify an agent capable of ‘boosting’ stem cells already present in muscle tissue for a more efficient tissue repair to tackle degenerative muscle disease. Muscular dystrophy is a type of degenerative muscle disease. One of its most known forms, Duchenne muscular dystrophy, affects 1 over 3 500 boys worldwide. It affects patients progressively, they […]

October 28, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 27 Oct 2014

Forendo Pharma Closes 12 Million Euros to Develop Novel Targeted Therapy

Forendo Pharma successfully closed €12M for further development of treatment against endometriosis. Novartis Venture Fund and MS Ventures will participate in the financing round, alongside the current major shareholders Karolinska Development, Novo A/S and Finnvera. Endometriosis is a chronic disease affecting up to 10% of the women between adolescence and menopause. There is a large unmet medical […]

October 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 24 Oct 2014

Only One Woman for Ten Men in 2014 Biotech Boards

The average board of directors in the biotech world is roughly 90% male, and more than half of all industry boardrooms host no women. Recent report from Lifestream release these striking numbers that illustrate a sector that struggles with diversity. Nearly 1,150 life sciences companies in the U.S. and EU, finding that biotech’s boardrooms tend […]

October 24, 2014 - 1 minutemin - By Julie Lellouche

News and Trends 23 Oct 2014

The First French Biotech entered successfully on the NASDAQ

DBV Technologies entered on the NASDAQ last Wednesday raising up to 90 million euros. It bets on treating peanut allergy, which is a major health issue in the United States, and targets up to one billion dollars revenues. The small French biotechnology company which has developed a new system of allergy desensitization based on skin patches launched […]

October 23, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us